zeltia ( Seite 40)

Antwort auf Beitrag Nr.: 42.074.793 von bonDiacomova am 12.09.11 13:41:42Ganz wirklos scheint das Zeug also nicht zu sein
Dann hoffe ich mal, dass sich das auch in den kommeden Umsätzen bemerkbar machen wird.

Antwort auf Beitrag Nr.: 42.082.487 von 7911793 am 13.09.11 20:17:25herzlichen glueckwunsch T
moege es ewig halten
seid nett zueinander *
* meine oma ©

saludos y suerte bd

dass sich das auch in den kommeden Umsätzen bemerkbar machen wird.

in den nun (27.10.) kommenden zahlen ....ich denke nicht....


27 - 29 de Octubre de 2011, CTOS chicago
27 - 29 de Octubre de 2011, Milan ESGO
16 - 19 Noviembre, en San Francisco, AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
10 - 13 de Diciembre, San DiegoASH Annual Meeting 2011

imho auch sehr wichtig
El 20 de noviembre - vorgezogene national (general) wahlen
die PP ( konservativen ) in der letzten umfrage die absolute mehrheit

Yondelis® approved for sale in 8 new countries

· The regulatory authorities in 8 countries have granted 11 sales authorisations for Yondelis®.

· Four of those authorisations are for Yondelis® in combination with Caelyx®
(pegylated liposomal doxorubicin) for treating relapsed platinum-sensitive ovarian cancer,
in Belarus, Egypt, El Salvador and Honduras.

· The other seven authorisations are for Yondelis® for soft tissue sarcoma,
in Bahrain, Belarus, Canada, Egypt, El Salvador, Indonesia and Qatar.

· Yondelis® is currently approved in 70 countries.

http://www.zeltia.com/Index.cfm?idIdioma=2

Antwort auf Beitrag Nr.: 42.268.171 von bonDiacomova am 27.10.11 18:15:38verkaeufe 9 monate yon : 56,6 mil

http://www.zeltia.com/analistas_inversores.cfm

engl. :
http://www.zeltia.com/analistas_inversores.cfm?idIdioma=2
LATEST FINANCIAL REPORTS
auf 3Q 2011 klicken

Beitrag Nr.377
(41.420.805)

Q I 2009 - 8,3 mil
Q II 2009 - 11,1 mil
Q III 2009 - 11,0 mil
Q IIII 2009 - 13,4 mil

http://www.wallstreet-online.de/community/posting-drucken.ph…

Q I 2010 - 16,6 mil
Q II 2010 - 17,0 mil
Q III 2010 - 18,2 mil
Q IIII 2010 - 20,5 mil

Q I 2011 - 19,6 mil
Q II 2011 - 18,6 mil
Q III 2011 - 18,4 mil

Antwort auf Beitrag Nr.: 41.773.702 von bonDiacomova am 12.07.11 06:50:34shorts gestern + 2.133.798

http://www.bolsamadrid.es/esp/bolsamadrid/publicacion/boleti…
auf 8. zeile (Operaciones a crédito, préstamo de valores) von oben

Federal inspectors say the contract manufacturer for Johnson & Johnson’s cancer drug Doxil
hasn’t been maintaining equipment or promptly investigating defective product batches
and other serious problems at its Bedford, Ohio, factory.
http://dailycaller.com/2011/12/08/fda-finds-serious-problems…

noscira
Noscira (Zeltia) tideglusib no mejora (verbessert nicht)
el estado clínico general en pacientes con PSP
http://www.invertia.com/noticias/articulo-final.asp?idNotici…

dieses resultat
soll den einsatz gegen alzheimer
nicht beeinflussen....

Zeltia, S.A. – informs that it’s subsidiary Pharma Mar, S.A., has come to an agreement
with Janssen Products LP, of Janssen Pharmaceutical Companies, on a new action plan to
pursue the development of Yondelis in the United States.

In this regard Janssen will perform a second pivotal Phase III trial with Yondelis in relapsed ovarian cancer(ROC).
Furthermore, Janssen will continue the Phase III study in L-Sarcoma.

Within the frame ofsaid agreement, PharmaMar gets a down-payment
of 25 million USDollars before the end of 2011.

Additionally PharmaMar will receive another 85 million USDollars for milestones
as they are reached, and only based on the development of Yondelis for the period between
2012-2015(25M in 2012, 25M in 2013, 25M in 2014 and 10M in 2015).
These milestones are additional to those already included in the original licensing agreement.

http://servicios.invertia.com/foros/read.asp?idMen=102310832…